Genetically guided statin therapy on statin perceptions, adherence, and cholesterol lowering: A pilot implementation study in primary care patients

Journal of Personalized Medicine

Volumn 4, Issue 2, 2014, Pages 147-162

  Li, Josephine H ^a   Joy, Scott V ^b   Haga, Susanne B ^a   Orlando, Lori A ^a   Kraus, William E ^a   Ginsburg, Geoffrey S ^a   Voora, Deepak ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Health behavior; Hyperlipidemia; Medication adherence; Personalized medicine; Pharmacogenetics; Risk assessment

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; BELIEFS ABOUT MEDICATIONS QUESTIONNAIRE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG UTILIZATION; FEMALE; GENE; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GENOTYPING TECHNIQUE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PERCEPTION; PHARMACOGENETICS; PILOT STUDY; PRESCRIPTION; PRIMARY HEALTH CARE; SLCO1B1 GENE;

EID: 84989804925     PISSN: None     EISSN: 20754426     Source Type: Journal    
DOI: 10.3390/jpm4020147     Document Type: Article

References (35)

1. Pasternak, R.C.; Smith, S.C., Jr.; Bairey-Merz, C.N.; Grundy, S.M.; Cleeman, J.I.; Lenfant, C. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation 2002, 106, 1024-1028.
2. Jackevicius, C.A.; Mamdani, M.; Tu, J.V. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002, 288, 462-467.
3. Ho, P.M.; Magid, D.J.; Shetterly, S.M.; Olson, K.L.; Maddox, T.M.; Peterson, P.N.; Masoudi, F.A.; Rumsfeld, J.S. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am. Heart J. 2008, 155, 772-779.
4. Pittman, D.G.; Chen, W.; Bowlin, S.J.; Foody, J.M. Adherence to statins, subsequent healthcare costs, and cardiovascular hospitalizations. Am. J. Cardiol. 2011, 107, 1662-1666.
5. Osterberg, L.; Blaschke, T. Adherence to medication. N. Engl. J. Med. 2005, 353, 487-497.
6. Mancini, G.B.; Baker, S.; Bergeron, J.; Fitchett, D.; Frohlich, J.; Genest, J.; Gupta, M.; Hegele, R.A.; Ng, D.; Pope, J. Diagnosis, prevention, and management of statin adverse effects and intolerance: Proceedings of a Canadian Working Group Consensus Conference. Can. J. Cardiol. 2011, 27, 635-662.
7. Cohen, J.D.; Brinton, E.A.; Ito, M.K.; Jacobson, T.A. Understanding Statin Use in America and Gaps in Patient Education (USAGE): An internet-based survey of 10,138 current and former statin users. J. Clin. Lipidol. 2012, 6, 208-215.
8. Jacobson, T.A. Toward -pain-free{norm of matrix} statin prescribing: Clinical algorithm for diagnosis and management of myalgia. Mayo Clin. Proc. 2008, 83, 687-700.
9. Garavalia, L.; Garavalia, B.; Spertus, J.A.; Decker, C. Exploring patients' reasons for discontinuance of heart medications. J. Cardiovasc. Nurs. 2009, 24, 371-379.
10. Fung, V.; Sinclair, F.; Wang, H.; Dailey, D.; Hsu, J.; Shaber, R. Patients' perspectives on nonadherence to statin therapy: A focus-group study. Perm. J. 2010, 14, 4-10.
11. Fernandez, G.; Spatz, E.S.; Jablecki, C.; Phillips, P.S. Statin myopathy: A common dilemma not reflected in clinical trials. Cleve Clin. J. Med. 2011, 78, 393-403.
12. Rallidis, L.S.; Fountoulaki, K.; Anastasiou-Nana, M. Managing the underestimated risk of statin-associated myopathy. Int. J. Cardiol. 2012, 159, 169-176.
13. Zhang, H.; Plutzky, J.; Skentzos, S.; Morrison, F.; Mar, P.; Shubina, M.; Turchin, A. Discontinuation of statins in routine care settings: A cohort study. Ann. Intern. Med. 2013, 158, 526-534.
14. Group, S.C.; Link, E.; Parish, S.; Armitage, J.; Bowman, L.; Heath, S.; Matsuda, F.; Gut, I.; Lathrop, M.; Collins, R. SLCO1B1 variants and statin-induced myopathy-A genomewide study. N. Engl. J. Med. 2008, 359, 789-799.
15. Voora, D.; Shah, S.H.; Spasojevic, I.; Ali, S.; Reed, C.R.; Salisbury, B.A.; Ginsburg, G.S. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J. Am. Coll. Cardiol. 2009, 54, 1609-1616.
16. Donnelly, L.A.; Doney, A.S.; Tavendale, R.; Lang, C.C.; Pearson, E.R.; Colhoun, H.M.; McCarthy, M.I.; Hattersley, A.T.; Morris, A.D.; Palmer, C.N. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: A go-DARTS study. Clin. Pharmacol. Ther. 2011, 89, 210-216.
17. Puccetti, L.; Ciani, F.; Auteri, A. Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. Atherosclerosis 2010, 211, 28-29.
18. Danik, J.S.; Chasman, D.I.; Macfadyen, J.G.; Nyberg, F.; Barratt, B.J.; Ridker, P.M. Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy. Am. Heart J. 2013, 165, 1008-1014.
19. Grundy, S.M.; Cleeman, J.I.; Merz, C.N.; Brewer, H.B., Jr.; Clark, L.T.; Hunninghake, D.B.; Pasternak, R.C.; Smith, S.C., Jr.; Stone, N.J. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110, 227-239.
20. Horne, R.; Weinman, J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J. Psychosom. Res. 1999, 47, 555-567.
21. Horne, R.; Weinman, J.; Hankins, M. The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication. Psychol. Health. 1999, 14, 1-24.
22. Phatak, H.M.; Thomas, J. Relationships between beliefs about medications and nonadherence to prescribed chronic medications. Ann. Pharmacother. 2006, 40, 1737-1742.
23. Green, R.C.; Roberts, J.S.; Cupples, L.A.; Relkin, N.R.; Whitehouse, P.J.; Brown, T.; Eckert, S.L.; Butson, M.; Sadovnick, A.D.; Quaid, K.A.; et al. Disclosure of APOE genotype for risk of Alzheimer's disease. N. Engl. J. Med. 2009, 361, 245-254.
24. Haga, S.B.; Lapointe, N.M. The potential impact of pharmacogenetic testing on medication adherence. Pharmacogenomics J. 2013, 13, 481-483.
25. Maningat, P.; Gordon, B.R.; Breslow, J.L. How do we improve patient compliance and adherence to long-term statin therapy? Curr. Atheroscler. Rep. 2013, 15, e291.
26. Nieuwkerk, P.T.; Nierman, M.C.; Vissers, M.N.; Locadia, M.; Greggers-Peusch, P.; Knape, L.P.; Kastelein, J.J.; Sprangers, M.A.; de Haes, H.C.; Stroes, E.S. Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with an increased cardiovascular risk. Am. J. Cardiol. 2012, 110, 666-672.
27. Charland, S.L.; Agatep, B.C.; Epstein, R.S.; Frueh, F.W.; Herrera, V.; Devlin, J.; Superko, H.; Stanek, E.J. Patient knowledge of pharmacogenetic information improves adherence to statin therapy: Results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) trial. J. Am. Coll. Cardiol. 2012, 59, doi:10.1016/S0735-1097(12)61849-X.
28. Iakoubova, O.A.; Tong, C.H.; Rowland, C.M.; Kirchgessner, T.G.; Young, B.A.; Arellano, A.R.; Shiffman, D.; Sabatine, M.S.; Campos, H.; Packard, C.J.; et al. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J. Am. Coll. Cardiol. 2008, 51, 435-443.
29. Iakoubova, O.A.; Sabatine, M.S.; Rowland, C.M.; Tong, C.H.; Catanese, J.J.; Ranade, K.; Simonsen, K.L.; Kirchgessner, T.G.; Cannon, C.P.; Devlin, J.J.; et al. Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: Results from the PROVE IT-TIMI 22 study. J. Am. Coll. Cardiol. 2008, 51, 449-455.
30. Stewart, A.F.; Dandona, S.; Chen, L.; Assogba, O.; Belanger, M.; Ewart, G.; LaRose, R.; Doelle, H.; Williams, K.; Wells, G.A.; et al. Kinesin family member 6 variant Trp719Arg does not associate with angiographically defined coronary artery disease in the Ottawa Heart Genomics Study. J. Am. Coll. Cardiol. 2009, 53, 1471-1472.
31. Assimes, T.L.; Holm, H.; Kathiresan, S.; Reilly, M.P.; Thorleifsson, G.; Voight, B.F.; Erdmann, J.; Willenborg, C.; Vaidya, D.; Xie, C.; et al. Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J. Am. Coll. Cardiol. 2010, 56, 1552-1563.
32. Hopewell, J.C.; Parish, S.; Clarke, R.; Armitage, J.; Bowman, L.; Hager, J.; Lathrop, M.; Collins, R. No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study. J. Am. Coll. Cardiol. 2011, 57, 2000-2007.
33. Horvath, M.M.; Winfield, S.; Evans, S.; Slopek, S.; Shang, H.; Ferranti, J. The DEDUCE Guided Query tool: providing simplified access to clinical data for research and quality improvement. J. Biomed. Inform. 2011, 44, 266-276.
34. Statin Therapy to Improve Medication Adherence - ClinicalTrials.gov. Available online: http://clinicaltrials.gov/ct2/show/NCT01894217 (accesssed on 18 March 2014).
35. R Development Core Team. R: A Language and Environment for Statistical Computing; R Foundation for Statistical Computing: Vienna, Austria, 2012.